Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133542 | 0.80 | THRB (0.36) | NAMPTGPR119TP53THRB | |
| SCHEMBL20557386 | 0.80 | ELANE (0.35) | PIK3CDPREPRECQLNR1H2 | |
| SCHEMBL5185542 | 0.79 | NR1H2 (0.37) | NAMPTGPR119NR1H2TP53THRB | |
| SCHEMBL4147632 | 0.78 | GPR119 (0.33) | PIK3CDPREPGPR119 | |
| SCHEMBL18114787 | 0.75 | DTYMK (0.31) | NR1H2 | |
| SCHEMBL3537808 | 0.74 | NPC1 (0.30) | — | |
| SCHEMBL21980428 | 0.73 | CCR5 (0.36) | GPR119 | |
| SCHEMBL20018574 | 0.72 | DUT (0.33) | — | |
| SCHEMBL4143177 | 0.72 | POLB (0.52) | GPR119TP53THRB | |
| SCHEMBL23372979 | 0.69 | NR1H2 (0.40) | NAMPTGPR119NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | PIK3CD 3317/4885PREP 1945/4885NAMPT 2639/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | PIK3CD 3317/4885PREP 1945/4885NAMPT 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.